University of Hyderabad, Krismo Biosciences partner to develop therapies for inflammatory & infectious diseases

Hyderabad: The University of Hyderabad (UoH) and Krismo Biosciences Private Limited, a biotechnology start-up incubated at ASPIRE-BioNEST, have announced a collaboration to develop new therapies for inflammatory diseases and serious infectious conditions.

The partnership brings together academic research and industry application to focus on developing antibody-based therapies. These will target viral infections such as Dengue, COVID-19, and Influenza, as well as bacterial toxins that cause severe illnesses like gas gangrene.

The collaboration will cover the early stages of drug development, including preclinical toxicology and non-GLP studies. Both parties also plan to jointly apply for research grants to support their efforts.

Prof. Nooruddin Khan, from the Department of Animal Biology, School of Life Sciences at UoH, said the collaboration combines academic expertise with industry experience to address urgent healthcare needs. Dr. Krishna Mohan, CEO of Krismo Biosciences, expressed confidence that the partnership would lead to practical and affordable treatments.

The initiative was facilitated by the University’s Technology Enabling Centre (UoH-TEC), supported by the Department of Science and Technology (DST), Government of India. Prof. S. Rajagopal, Project Coordinator at UoH-TEC, highlighted the center’s role in encouraging faculty to turn research into viable technologies. He thanked the DST for its continued support and reiterated UoH-TEC’s commitment to connecting researchers with industry partners.

Dr. Sunil, Principal Scientific Officer at UoH-TEC, and Dr. Anil Kondreddy, CEO of ASPIRE-BioNEST, were also present at the agreement signing ceremony.